FindTrial
Sign In

Development of Novel Immunotherapy for Cancer

Development of Novel Immunotherapy for Cancer - Development of Novel Immunotherapy for Cancer

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000052314
Enrollment
20
Registered
2023-10-01
Start date
2023-07-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liquid and Solid Tumors

Interventions

None listed

Sponsors

Ehime University Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy Donors and Cancer Patients

Exclusion criteria

Exclusion criteria: Donors whose Hb values are less than 9.0 g/dL.

Design outcomes

Primary

MeasureTime frame
Efficacy and safety of gene-modified immune cells and antibodies.—

Countries

Japan

Contacts

Public ContactToshiki Ochi

Ehime University Graduate School of Medicine Department of Hematology, Clinical Immunology and Infectious Diseases

ochi.toshiki.eg@ehime-u.ac.jp089-960-5296

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026